Skip to main content
. 2010 Aug 10;1(4):278–294.

Table 4.

Associations between treatment outcomes and XPD hapiotypes, effect of AML onset

CR in de novo AML CR in secondary AML
Haplotype group Total N
N1* OR/HR CI N1* OR/HR CI
AA/AC/BB/BC/CC 151 62 1.00 14 1.00
DA/DB/DC/DD 122 58 1.08 0.58–2.02 12 1.92 0.64–5.75
Total 273 120 26

AA** 105 43 1.00 5 1.00
DA 18 8 1.25 0.34–4.64 2 10.55 0.45–287.48
DC 85 41 1.42 0.68–2.45 9†† 7.73 1.36–59.24
Other 65 28 1.79 0.75–4.26 10†† 5.05 0.98–34.50

AA (‘0’ variant alleles) 105 43 1.00 5 1.00
AC/DA (1 variant allele) 29 12 1.13 0.39–3.29 2 4.32 0.24–72.29
CC/DD/DC (2 variant alleles) 89 43 1.52 0.73–3.13 9†† 6.35 1.14–47.16
BC/DB (3 variant alleles) 26 12 1.28 0.34–4.78 3 2.99 0.31–28.12
BB (4 variant alleles) 24 10 2.54 0.70–9.21 7†† 18 31 2 08–283 57

OS in de novo AML OS in secondary AML
AA/AC/BB/BC/CC 151 77 1.00 41 1.00
DA/DB/DC/DD 122 70 1.06 0.77–1.47 24 0.70 0.41–1.21
Total 273 147 65

AA** 105 55 1.00 25 1.00
DA 18 7 0.69 0.31–1.52 5 0.62 0.21–1.83
DC 85 54 1.15 0.79–1.68 14 0.41 0.20–0.83
Other 65 31 1.33 0.79–2.23 21 0.61 0.30–1.23

AA (‘0’ variant alleles) 105 55 1.00 25 1.00
AC/DA (1 variant allele) 29 14 0.94 0.52–1.69 8 0.60 0.25–1.45
CC/DD/DC (2 variant alleles) 89 55 1.13 0.78–1.65 16 0.44 0.23–0.87
BC/DB (3 variant alleles) 26 12 1.40 0.73–2.68 8 0.58 0.25–1.35
BB (4 variant alleles) 24 11 1.09 0.56–2.11 8 0.31 0.14–0.73
*

N1=number of CR/deaths with certain haplotype

**

models adjusted for age, cytogenetic group, AML onset (if not stratified), HSCT, WBC count

Exact OR and CR are calculated

††

p-value=0.02 (DC), 0.05 (Other), 0.03 (CC/DD/DC), 0.004 (BB) accordingly